Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma.

Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, McGuire KP, Johnson RR, Badve P, Puhalla SL, Bhargava R.

Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):334-9. doi: 10.1097/PAI.0b013e31823f4663.

PMID:
22417856
2.

Morphologic features do not influence response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.

Li X, Kanbour-Shakir A, Dabbs DJ, Bhargava R.

Appl Immunohistochem Mol Morphol. 2013 Oct;21(5):420-5. doi: 10.1097/PAI.0b013e318273c1cc.

PMID:
23165332
3.

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.

Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Nov 1;7:203.

4.

Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.

Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, Pusztai L.

Clin Cancer Res. 2010 Jan 15;16(2):711-8. doi: 10.1158/1078-0432.CCR-09-2247. Epub 2010 Jan 12.

5.
6.

Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.

Iwata H, Sato N, Masuda N, Nakamura S, Yamamoto N, Kuroi K, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Toi M.

Jpn J Clin Oncol. 2011 Jul;41(7):867-75. doi: 10.1093/jjco/hyr081.

PMID:
21719750
7.

Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.

Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6862-70. eCollection 2014.

8.

Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L.

Clin Cancer Res. 2010 Nov 1;16(21):5351-61. doi: 10.1158/1078-0432.CCR-10-1265. Epub 2010 Sep 9.

9.

Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.

Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B.

Clin Breast Cancer. 2011 Apr;11(2):129-34. doi: 10.1016/j.clbc.2011.03.002. Epub 2011 Apr 11.

PMID:
21569999
10.

Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.

Bhargava R, Beriwal S, McManus K, Dabbs DJ.

Appl Immunohistochem Mol Morphol. 2011 May;19(3):218-25. doi: 10.1097/PAI.0b013e3181ffc58c.

PMID:
21217522
11.

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.

Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL Jr, Sharkey FE, Cruz AB, Kahlenberg MS.

Cancer. 2005 Jun 1;103(11):2252-60.

12.

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.

Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC.

Clin Cancer Res. 2010 Dec 15;16(24):6159-68. doi: 10.1158/1078-0432.CCR-10-1027. Epub 2010 Aug 27.

13.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
14.

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.

Cancer. 2010 Mar 15;116(6):1431-9. doi: 10.1002/cncr.24876. Erratum in: Cancer. 2011 May 15;117(10):2238.

15.

Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.

Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF.

Cancer. 2004 Apr 1;100(7):1365-73.

16.

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.

Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ.

J Clin Oncol. 2005 May 20;23(15):3331-42.

PMID:
15908647
17.

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ.

Breast Cancer Res. 2011 Mar 2;13(2):R22. doi: 10.1186/bcr2834.

18.

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.

Oncology. 2011;80(3-4):269-77. doi: 10.1159/000329038. Epub 2011 Jul 7.

PMID:
21734419
19.

Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.

Sánchez-Muñoz A, Navarro-Perez V, Plata-Fernández Y, Santonja A, Moreno I, Ribelles N, Alba E.

Clin Breast Cancer. 2015 Oct;15(5):343-7. doi: 10.1016/j.clbc.2015.01.005. Epub 2015 Jan 21.

PMID:
25752727
20.

Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.

Naoi Y, Kishi K, Tanei T, Tsunashima R, Tominaga N, Baba Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S.

Cancer. 2011 Aug 15;117(16):3682-90. doi: 10.1002/cncr.25953. Epub 2011 Feb 8.

Supplemental Content

Support Center